为您找到相关结果约500个

你是不是要搜索 期刊EGFR突变型非小细胞肺癌（NSCLC） 点击跳转

EGFR-mutant NSCLC: emerging novel drugs

Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression

Osimertinib in Resected EGFR-Mutated NSCLC

NSCLC with EGFR-Mutation: Benefits of Osimertinib

Urea Cycle Sustains Cellular Energetics upon EGFR Inhibition in EGFR-Mutant NSCLC

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

Musashi-2 regulates EGFR expression in NSCLC, cell proliferation and survival, response to EGFR inhibitorsin EGFR-mutant NSCLC

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth

EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC

EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors

Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs

Exosomal non-coding RNAs-mediated EGFR-TKIs resistance in NSCLC with EGFR mutation

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure

Y Radiomic Detection of EGFR Mutations in NSCLC

为您找到相关结果约500个

共500条页码: 1/34页15条/页